scholarly journals Research and Development of New Drugs Against Tuberculosis

10.5772/54278 ◽  
2013 ◽  
Author(s):  
Juan D. ◽  
Ximena Montes-Rincon ◽  
Wellman Ribo
Keyword(s):  
Research And Development ◽  
New Drugs

Studying the peculiarities of project and program management in the pharmaceutical companies on Russian market

2018 ◽  
Vol 7 (1) ◽  
pp. 19-33
Author(s):  
Екатерина Фролкина ◽  
Ekaterina Frolkina
Keyword(s):  
Life Cycle ◽  
Research And Development ◽  
Business Processes ◽  
Program Management ◽  
New Drugs ◽  
Pharmaceutical Companies ◽  
Development Projects ◽  
Russian Market ◽  
Key Features ◽  
A Company

The author singled out a typology of projects in pharmaceutical companies for the life cycle of the creation and commercializing of a new drug on the market, including research and development projects, production projects and implementation projects. In the framework of the study, the author examined only implementation projects, namely: projects for introducing new drugs to the market, projects to maintain existing drugs on the market and projects to optimize business processes. The purpose of this study was to identify key features of managing projects and programs in pharmaceutical companies operating on the Russian market, to form an approach to managing a company that increases its competitiveness.

Research and Development Costs of New Drugs

JAMA ◽  
2020 ◽  
Vol 324 (5) ◽  
pp. 516
Author(s):  
Bart Dierynck ◽  
Philip Joos
Keyword(s):  
Research And Development ◽  
New Drugs ◽  
Development Costs

Research and Development Costs of New Drugs

JAMA ◽  
2020 ◽  
Vol 324 (5) ◽  
pp. 516
Author(s):  
Luis W. Dominguez ◽  
Joel S. Willis
Keyword(s):  
Research And Development ◽  
New Drugs ◽  
Development Costs

A philosophy for Opening Biotechnology Collaboration for Therapeutics

2017 ◽  
Author(s):  
Jason Barkeloo ◽  
Timothy Cripe ◽  
Li Guo ◽  
Ronald Laymon ◽  
Pablo Pomposiello ◽  
...  
Keyword(s):  
Synthetic Biology ◽  
Research And Development ◽  
Open Source ◽  
Patent Protection ◽  
Pharmaceutical Research ◽  
New Drugs ◽  
Regulatory Requirements ◽  
Drug Candidates ◽  
Technological Advances ◽  
Prescription Costs

The pharmaceutical industry faces a host of worsening problems: Multibillion-dollar expenses and decade-long development times to bring new drugs to market, high failure rates for new drug candidates, and a patent system that is both expensive and uncertain. Demanding regulatory requirements and governmental pressures on prescription costs add yet more pressure on drug development. Although the situation does not yet constitute a crisis, its current trajectory is becoming increasingly untenable. While the industry itself has been resourceful in introducing technological advances and operating reforms such as increased collaboration through patent pooling, these efforts do not exhaust the possibilities for improvement. In particular, there has been an emerging, more agile and responsive alternative model in pharmaceutical research and development, namely open source synthetic biology – a rapidly developing and highly collaborative effort based on engineering principles involving the design and construction of biological systems using standardized modules of DNA. Synthetic biology began entirely open to those who wished to participate, provided that they agreed to share their results without restrictions. In its current and more mature state, it retains much of its open source character and is consequently less dependent on secrecy and patent protection than the pharmaceutical industry’s largely proprietary approach. The success of open source synthetic biology has inspired us to further develop that approach for research and development in Biotechnology and its pharmaceutical applications. Here, we reviewed the history and progress of open source science and technology.

Pharmaceuticals, Patents, and Politics: Canada and Bill C-22

1993 ◽  
Vol 23 (1) ◽  
pp. 147-160 ◽  
Author(s):  
Joel Lexchin
Keyword(s):  
United States ◽  
Research And Development ◽  
Patent Protection ◽  
The United States ◽  
New Drugs ◽  
Compulsory Licensing ◽  
High Drug ◽  
Drug Prices ◽  
Future Demands ◽  
The Impact

In response to high drug prices, the Canadian government amended the country's patent act in 1969 to allow for compulsory licensing to import pharmaceuticals. As a result of the legislation, by 1983 drug costs in Canada were over $200 million lower than they would otherwise have been. The multinational drug industry was strongly opposed to compulsory licensing, despite any evidence that its economic position had been harmed. Restoration of patent protection for drugs was one of the key U.S. demands during free-trade negotiations between Canada and the United States in 1985–1987. The result was Bill C-22, which gave new drugs protection from compulsory licensing for seven to ten years. This article analyzes the impact of Bill C-22 on the generic industry, the creation of jobs in research and development, drug prices, and research and development expenditures. It concludes with an examination of future demands from the pharmaceutical industry.

Ethnobotanical Study of Traditional Medicinal Plants used as Anti-Psoriatic in Rajasthan

2016 ◽  
Vol 23 (4) ◽  
pp. 225-232
Author(s):  
M. Singhadiya ◽  
Isha Pandey ◽  
Vinod Maina ◽  
R. Pandey ◽  
Peddy Harikrishna
Keyword(s):  
Medicinal Plants ◽  
Research And Development ◽  
Traditional Knowledge ◽  
Indigenous People ◽  
Plant Species ◽  
New Drugs ◽  
Ethnobotanical Study ◽  
Plant Parts ◽  
Traditional Medicinal Plants ◽  
Ethnomedicinal Plant

The present study deals with 26 ethnomedicinal plant species belonging to 17 families used as antipsoriatic by the indigenous people in Rajasthan. The study also deals with types of Psoriasis, plant name, local name, family name, plant parts and mode in the treatment of psoriasis. The present study also gathered important information about traditional knowledge and the need to document, research and development of new drugs to fight against Psoriasis disease in Rajasthan in particular and India as a whole.

Design, synthesis and biological evaluation of a hybrid compound of berberine and magnolol for improvement of glucose and lipid metabolism

RSC Advances ◽  
2016 ◽  
Vol 6 (85) ◽  
pp. 81924-81931 ◽  
Author(s):  
Yan Li ◽  
Xiao Yuan ◽  
Xianglu Rong ◽  
Ying Gao ◽  
Zhibin Qiu ◽  
...  
Keyword(s):  
Lipid Metabolism ◽  
Research And Development ◽  
Biological Evaluation ◽  
New Drugs ◽  
Main Task ◽  
Hybrid Compound ◽  
Design Synthesis ◽  
Lead Compounds ◽  
Glucose And Lipid Metabolism ◽  
Synthesis And Biological Evaluation

The discovery and structural optimization of lead compounds is the main task in the research and development of new drugs.

Sign in / Sign up

Export Citation Format

Share Document